Uplizna (Inebilizumab)

Uplizna (inebilizumab) is an intravenous infusion therapy for certain autoimmune conditions. This biologic targets specific immune cells to support disease management. It is prescribed under medical supervision for targeted immunomodulation. Suitable for patients seeking advanced treatment options for relapsing forms of multiple sclerosis.

Uplizna is primarily used to treat relapsing forms of multiple sclerosis (MS), helping to reduce the frequency of relapses and delay progression. It is also prescribed for neuromyelitis optica spectrum disorder (NMOSD) to reduce the risk of relapse. Patients often ask, 'what is inebilizumab used for' when exploring treatment options for autoimmune conditions. This therapy works by targeting CD19-positive B cells to modulate the immune response.

Common effects of Uplizna may include infusion-related reactions such as headache, nausea, or fever during or after administration. Some patients report fatigue or dizziness following treatment. These effects are typically monitored by healthcare professionals to ensure patient comfort and safety. Individual responses may vary based on medical history and concurrent therapies.

Uplizna should be administered by healthcare professionals in a controlled setting due to the risk of infusion reactions. Patients with active infections or compromised immune systems may need to delay treatment until resolved. Regular monitoring is recommended to assess response and manage potential side effects. Always disclose full medical history to your healthcare provider before starting therapy.

Uplizna may interact with other immunosuppressants or live vaccines, potentially increasing infection risk. Combining with strong CYP inhibitors could affect drug levels, though specific interactions vary. Patients should inform their doctor about all medications, including over-the-counter and herbal supplements. Alcohol use may exacerbate certain side effects and should be discussed with a healthcare provider.